- Pharmaceutical Products
- Products By Brand Name
- Products By Dosage Form
- Products By Generic Name
- Products By Therapeutic Class
Find a product
Find Generic
Vonliv
Vonoprazan Fumarate
Description:
Vonliv® contains Vonoprazan which is a potassium competitive acid blocker (PCAB). Chemically, Vonoprazan is 1-[5-(2-fluorophenyl) -1- (pyridin-3-yIsuIfonyl)- 1H-pyrroI-3-yI]- N-methylmethanamine monofumarate. Its molecular formula is CJzHJsFNaOzS.C4HsO4
Vonliv® contains Vonoprazan which is a potassium competitive acid blocker (PCAB). Chemically, Vonoprazan is 1-[5-(2-fluorophenyl) -1- (pyridin-3-yIsuIfonyl)- 1H-pyrroI-3-yI]- N-methylmethanamine monofumarate. Its molecular formula is CJzHJsFNaOzS.C4HsO4
Indications:
1. Gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin administration, prevention of recurrence of gastric or duodenal ulcer during non-steroidal anti-inflammatory drug (NSAID) administration. 2. Adjunct to Helicobacter pylori eradication in the following settings: Gastric ulcer, Duodenal ulcer, Gastric Mucosa-Associated Lymphatic Tissue (MALT) lymphoma, Idiopathic thrombocytopenic purpura and Helicobacter pylori gastritis.
1. Gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin administration, prevention of recurrence of gastric or duodenal ulcer during non-steroidal anti-inflammatory drug (NSAID) administration. 2. Adjunct to Helicobacter pylori eradication in the following settings: Gastric ulcer, Duodenal ulcer, Gastric Mucosa-Associated Lymphatic Tissue (MALT) lymphoma, Idiopathic thrombocytopenic purpura and Helicobacter pylori gastritis.
Mode of Action:
Vonoprazan does not require activation by acid. It inhibits H+, K+-ATPase in a reversible and potassium-competitive manner. Vonoprazan has a strong basicity and resides on the acid production site of gastric parietal cells for a long time, thereby inhibiting gastric acid production. Vonoprazan exens a strong inhibitory effect on formation of mucosal damage in upper part of the gastrointestinal tract.
Vonoprazan does not require activation by acid. It inhibits H+, K+-ATPase in a reversible and potassium-competitive manner. Vonoprazan has a strong basicity and resides on the acid production site of gastric parietal cells for a long time, thereby inhibiting gastric acid production. Vonoprazan exens a strong inhibitory effect on formation of mucosal damage in upper part of the gastrointestinal tract.
Other Brands From Same Therapeutic Class
